ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC raised its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 68.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 327,505 shares of the biopharmaceutical company’s stock after acquiring an additional 132,906 shares during the quarter. Fisher Asset Management LLC’s holdings in ACADIA Pharmaceuticals were worth $6,010,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ACAD. Quest Partners LLC raised its position in shares of ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 1,047 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in ACADIA Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 1,066 shares during the last quarter. KBC Group NV grew its stake in ACADIA Pharmaceuticals by 67.0% during the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 2,044 shares in the last quarter. Atria Investments Inc raised its holdings in ACADIA Pharmaceuticals by 10.8% in the 3rd quarter. Atria Investments Inc now owns 24,437 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 2,384 shares during the last quarter. Finally, Advisors Asset Management Inc. lifted its stake in ACADIA Pharmaceuticals by 13.4% in the 3rd quarter. Advisors Asset Management Inc. now owns 21,087 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 2,499 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on ACAD. Deutsche Bank Aktiengesellschaft began coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. StockNews.com lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Stock Performance

ACADIA Pharmaceuticals stock opened at $18.26 on Wednesday. The company has a market capitalization of $3.04 billion, a P/E ratio of 23.41 and a beta of 0.37. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $14.15 and a fifty-two week high of $24.27. The stock has a 50-day simple moving average of $18.44 and a 200-day simple moving average of $16.88.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.